Emergency doctors standardize cannabis sickness treatment for teens

Cannabis hyperemesis syndrome (CHS) is an increasingly recognized condition in adolescents who use cannabis, characterized by severe, cyclic episodes of nausea and vomiting. This study examined how implementing a standardized treatment protocol in a pediatric emergency department affected patient care. Researchers tracked 128 encounters involving 44 adolescents over a four-year period, comparing outcomes before and after introducing the management algorithm. The protocol emphasized the use of specific medications like capsaicin (a topical heat compound) and metoclopramide (an anti-nausea medication), while also adjusting how haloperidol was administered.

After the algorithm was put in place, the results showed significantly increased use of capsaicin (from 2.7% to 22.2%) and metoclopramide (from 6.8% to 42.6%), indicating that clinicians were following the new standardized approach. Haloperidol doses were also reduced while maintaining similar frequency of use. However, despite these changes in medication use patterns, the study found no significant difference in hospital admission rates or emergency department length of stay, suggesting that the algorithm improved treatment consistency without changing ultimate patient outcomes in these measured areas.

This research highlights an important gap in pediatric medicine: CHS is increasingly common but lacks well-established treatment guidelines. While the study demonstrates that standardized algorithms can successfully change clinical practice patterns, it suggests that optimal management of CHS in adolescents requires further investigation through prospective studies. The findings are particularly relevant for cannabis-using youth and their families, as they point toward the need for better understanding of which treatments most effectively address the underlying pathophysiology of this syndrome.